<DOC>
	<DOCNO>NCT02716610</DOCNO>
	<brief_summary>Pharmacokinetic ( PK ) Pharmacodynamic ( PD ) dose-response investigation Dance-501 inhale human insulin</brief_summary>
	<brief_title>Dose-Response Variability Inhaled Insulin Type 2 Diabetes</brief_title>
	<detailed_description>This study investigate pharmacokinetic ( PK ) pharmacodynamic ( PD ) property Dance-501 , novel inhale human insulin liquid formulation ( INH ) device . Twenty-four subject type 2 diabetes ( T2DM ) receive 3 INH dos : low ( 69 unit ) , medium ( 139 unit ) high ( 208 unit ) 1 equivalent medium dose ( 18 unit ) subcutaneous insulin lispro ( LIS ) . The medium dose repeat determine within subject variability . PD investigate 12 hour euglycemic clamp .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Type 2 diabetes mellitus treat insulin injection total daily dose less 1.2 U/kg/day . Body mass index 2540 kg/m2 Hemoglobin A1c 6.59.5 % Forced vital capacity force expiratory volume 1 second least 75 % predict normal value . Fasting cpeptide less 1 nmol/L Any condition possibly affect drug absorption lung , particular subject decrease lung function subject take bronchodilator subject smoke . Active chronic pulmonary disease . Any major disorder type 2 diabetes . Decompensated heart failure myocardial infarction time angina pectoris within last 12 month . Proliferative retinopathy maculopathy severe neuropathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>